SARM Safety & Legality
Mislabeling, the SARMs Control Act, FDA/FTC enforcement, and why none are approved
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- No SARM is FDA approved for human use; all are unapproved new drugs
- WADA
- SARMs prohibited at all times in sport (S1.2 Other Anabolic Agents)
Reference only. Not medical advice.
What can go wrong
Shared class risks: HPTA suppression (reduced testosterone, LH, FSH), reductions in HDL cholesterol, and SARM-associated drug-induced liver injury, including hospitalization-level cases. Overlaid on this is pervasive mislabeling and contamination, so actual exposure is unknown. Non-SARM chemicals sold alongside carry their own signals, cardarine's animal carcinogenicity, MK-677's glucose/edema effects. All are prohibited in WADA sport and are frequent doping-positive sources, sometimes via contaminated supplements.
This is something to take to a clinician. The Atlas can tell you what is known about sarm safety & legality in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
This synthesis monograph covers the shared safety and legal reality of SARMs and the 'research chemicals' sold with them. No SARM is FDA-approved for human use, all are unapproved new drugs, and the FDA warns they are illegally marketed as supplements or 'research chemicals.' A landmark 2017 JAMA analysis found that a majority of products marketed as SARMs were mislabeled or contained unlisted drugs. The proposed SARMs Control Act (2018) has not passed, but FDA/FTC warning letters and criminal prosecutions have increased.
The honest bottom line: no SARM is approved, the bottles rarely match their labels, and the law is closing in.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
As a class, SARMs are androgen-receptor agonists with relative tissue selectivity; the non-SARM 'research chemicals' sold with them (cardarine/PPAR-delta, SR9009/REV-ERB, MK-677/GH secretagogue) act by entirely different mechanisms. What they share commercially is a gray-market supply chain and 'not for human consumption' labeling used to sidestep drug regulation.
Why 'none are approved' is the key fact
Every clinical SARM program that reached late stages either failed a functional endpoint (enobosarm's POWER trials) or never reached approval. The FDA classifies SARMs as unapproved new drugs that cannot be lawfully sold as supplements. Combined with the documented mislabeling and contamination problem, this means consumers cannot know what compound, at what dose, they are actually taking, the central safety fact of the category.
Safety in detail
No SARM is FDA-approved for human use. These are unapproved drugs with documented endocrine and hepatic risks, sold through a supply chain with pervasive mislabeling. Self-administration without medical oversight carries documented, and often unknowable, health risks.
Replacement is not the same as a cycle
Because consumer products are unregulated and frequently mislabeled, users routinely take unknown compounds at unknown, often supraphysiological doses, amplifying suppression, lipid and hepatic risk beyond anything studied.
What it does to fertility
SARMs suppress LH/FSH and endogenous testosterone, which can impair spermatogenesis; S-23 was studied specifically as a male contraceptive. Recovery is reported in short trials but is not guaranteed at chronic consumer doses.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Total/free testosterone, LH, FSH
- Lipid panel (HDL)
- Liver function tests (AST/ALT/bilirubin)
- Hematocrit
- For non-SARMs sold alongside: glucose/IGF-1 (MK-677)
What people get wrong
Often saidSARMs are legal supplements
ActuallyThey are unapproved new drugs; the FDA states they cannot be lawfully marketed as dietary supplements.
Often saidThe label tells you what is in the bottle
ActuallyIn the 2017 JAMA analysis a minority of products matched their label; many contained unlisted drugs or no active compound.
Often saidSARMs are a safe alternative to steroids
ActuallyThey suppress the HPT axis, alter lipids, and have caused severe liver injury; 'safe' is not supported.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
How we got here
As SARM sales exploded in the 2010s, evidence of mislabeling and harm accumulated: the 2017 JAMA analysis (with USADA and USUHS collaborators) exposed widespread label inaccuracy; the FDA issued consumer warnings and warning letters framing SARMs as unapproved drugs and citing liver injury. In 2018, Senators Orrin Hatch and Sheldon Whitehouse introduced the SARMs Control Act to place SARMs under DEA scheduling; it was reintroduced but never enacted. Meanwhile the FDA moved from warning letters toward criminal prosecutions of manufacturers and distributors, securing convictions.
- 2017JAMA analysis documents widespread SARM mislabeling
- 2018SARMs Control Act introduced (Hatch/Whitehouse); not enacted
- 2020sFDA consumer warnings; escalation to warning letters and criminal prosecutions
- OngoingNo SARM FDA-approved for human use
What we do not know
- Will SARMs be scheduled federally, or remain unapproved-drug gray market?
- Can any SARM demonstrate functional benefit, not just lean-mass change, in humans?
- How large is the true burden of SARM-related liver injury given underreporting?
At a glance
- FDA-approved SARMs
- Zero
- JAMA 2017 label accuracy
- ~41% matched label
- SARMs Control Act
- Introduced 2018; not enacted
- Legal status
- Unapproved new drugs
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about SARM Safety & Legality. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Van Wagoner, Eichner, Bhasin et al., chemical analysis of internet SARMs (JAMA)2017
Of 44 products, only ~52% contained a SARM; ~41% matched the label; some contained unapproved drugs or no active compound
FDA Consumer Update / warning: SARMs among teens and young adults2020s
FDA warns of liver injury and other harms; SARMs not lawful as supplements
Case reports of SARM-associated hepatotoxicity (RAD-140 and others)2022-2024
Severe cholestatic liver injury in young users; class safety signal